ArticleFrontiers in endocrinology2025
Association of triglyceride-glucose index and remnant cholesterol levels with liver fibrosis progression and disease severity in patients with non-alcoholic fatty liver disease: a cross-sectional study.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The associations of the triglyceride-glucose (TyG) index and remnant cholesterol (RC) with NAFLD severity (mild, moderate, and severe) and liver fibrosis remain unclear. This study examined these relationships and assessed the impact of TyG\RC on liver fibrosis. Methods: 594356 participants undergoing annual physical and ultrasonic examinations were included. Standardized questionnaires collected clinical data, and venous blood samples were measured for complete blood count, liver function, and metabolic parameters. TyG index and RC values were calculated, and liver fibrosis assessed using the NAFLD fibrosis score (NFS) and aspartate aminotransferase-to-platelet ratio index (APRI). Participants were categorized into TyG and RC levels quartiles (Q1-Q4) to examine their association with NAFLD severity. Sensitivity analyses were conducted subsequent to multiple imputation application for missing values and outliers. Results: 102599 NAFLD patients (75414 mild, 19412 moderate, 7733 severe) were included. RC exacerbated disease progression (odds ratio (OR) = 1.336, 95% confidence interval (CI): 1.163-1.537), whereas TyG index can inhibit it (OR = 0.436, 95% CI: 0.224-0.848). Compared with Q1 of TyG, participants in Q2 (OR = 0.897, 95% CI: 0.852-0.944) and Q3 (OR = 0.883, 95% CI: 0.839-0.930) inhibited the risk of NAFLD progression. Conversely, higher RC quartiles (Q2: OR = 1.114, 95% CI: 1.064-1.168; Q3: OR = 1.103, 95% CI: 1.048-1.149; Q4: OR = 1.251, 95% CI: 1.195-1.310) aggravated NAFLD progression. Additionally, sensitivity analyses yielded consistent results that were consistent with those of the initial analysis. Linear regression indicated that each 1-unit rise in TyG correlated with NFS (β = 0.407, 95% CI: 0.271-0.544) and APRI (β = 0.035, 95% CI: 0.034-0.037) increases, while a 1-unit RC increase corresponded to NFS (β = 0.791, 95% CI: 0.725-0.857) and APRI (β = 0.011, 95% CI: 0.010-0.012) elevations. Conclusion: The TyG index and RC may independently influence NAFLD progression and hepatic fibrosis. Elevated levels of both biomarkers contribute to fibrosis development, highlighting their utility in risk stratification and potential as therapeutic targets.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.